Tiny study reveals how a new brain drug travels through the body
NCT ID NCT03783000
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This completed phase 1 trial enrolled 6 healthy men to measure how much of the experimental drug BI 425809 reaches the bloodstream when taken as a pill compared to a tiny IV dose. Participants received one 25 mg tablet and later a radioactive microtracer injection. The goal is to understand the drug's oral bioavailability, which helps determine proper dosing for future studies in conditions like Alzheimer's disease or schizophrenia.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- BI 425809 (Iclepertin)
- What this could lead to
- If successful, this study will help determine the right oral dose of BI 425809 for future trials in conditions like Alzheimer's or schizophrenia.
- What could go wrong
- This is a very small, early-phase study in healthy volunteers, not patients. The drug may not work for any disease, and side effects are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
ICON
Groningen, 9728 NZ, Netherlands
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a new oral drug change future treatments? early safety trial begins
- Can brain scans unlock the secret to hearing in crowded rooms?
- Can a Light-Guided device make arterial sticks easier?
- Water workouts could be the key to back pain relief
- Could everyday disinfectants be harming us? a new study investigates
- Can a new drug keep the Heart's beat steady? trial puts verducatib to the test